Valeant posts FY23 revenue of $7.8 bln, up 42% YoY.
ByAinvest
Tuesday, Jan 13, 2026 11:51 am ET1min read
BHC--
BLCO--
• Valeant Pharmaceuticals International reports unaudited pro forma condensed combined financial information • Gives effect to Bausch & Lomb acquisition by Valeant and Medicis acquisition by Valeant • Includes debt and equity issuance to finance Bausch & Lomb acquisition • Medicis acquisition took place on December 11, 2012 • Valeant issued term loan and senior notes to finance Medicis acquisition • Unaudited pro forma condensed combined statements of loss for fiscal year ended December 31, 2012, and three months ended March 31, 2013.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet